salmeterol xinafoate

salmeterol xinafoate (AIREXAR SPIROMAX) is an FDA-listed pharmaceutical active ingredient. Associated with Teva Pharma GmbH. Route of administration: inhalation. Current US regulatory status: approved.

AIREXAR SPIROMAX is a marketed brand name for salmeterol xinafoate. Check FDA Drugs@FDA for the current US label holder and prescribing information.

salmeterol xinafoate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.